Avva Rus, JSC   Report issue

For profit Phase 3
Founded: Limassol Cyprus (1996)
Status: No NME R&D (1996)

Organization Overview

First Clinical Trial
2010
NCT01124318
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (4)

lactulose (cephulac) (2 trials)

lignin (1 trial)

lignin hydrolytic (1 trial)

metronidazole (flagyl) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenovirus Infections, Human (Phase 3)

Dermatitis (Phase 3)

Dermatitis, Atopic (Phase 3)

Eczema (Phase 3)

Enteritis (Phase 3)

Enterovirus Infections (Phase 3)

Gastroenteritis (Phase 3)

Vaginal Diseases (Phase 3)

Vaginosis, Bacterial (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 4